Leading the way to safer medication
 Crosscheck  Recommender

ATC Group: A02BA H2-receptor antagonists

Anatomical Therapeutic Chemical Classification System

Hierarchical Position

Level
Code
Title
1
A
Alimentary tract and metabolism
2
A02
Drugs for acid related disorders
3
A02B
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
A02BA
H2-receptor antagonists

Contents

Code
Title
A02BA01
Cimetidine
A02BA02
Ranitidine
A02BA03
Famotidine
A02BA04
Nizatidine
A02BA05
Niperotidine
A02BA06
Roxatidine
A02BA07
Ranitidine bismuth citrate
A02BA08
Lafutidine
A02BA51
Cimetidine, combinations
A02BA53
Famotidine, combinations

Active Ingredients

Chemical substance
Description
Cimetidine

Cimetidine is a histamine H2-receptor antagonist which rapidly inhibits both basal and stimulated gastric secretion of acid and reduces pepsin output. It is a reversible, competitive antagonist, and is used as an anti-ulcer drug.

Famotidine

Famotidine is a potent competitive H2-receptor antagonist. Famotidine has a rapid onset of action and, at the recommended doses, has a long duration of action and is highly effective at relatively low blood concentrations.

Nizatidine

Nizatidine is a potent, selective, competitive and fully reversible histamine H2-receptor antagonist. Nizatidine significantly decreased basal and stimulated gastric acid and pepsin concentration, in addition to the volume of gastric secretion.

Ranitidine

Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150 mg dose effectively suppresses gastric acid secretion for twelve hours.

Roxatidine

Roxatidine is a competitive histamine H2 receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

Monographs

Monograph
Type
Country
PEPCID AC Film-coated tablet
MPI, EU: SmPC
IE
PEPCID Film-coated tablet
MPI, US: SPL/PLR
US
PEPCID Oral suspension
MPI, US: SPL/PLR
US
Tagamet 200mg Tablets
MPI, EU: SmPC
UK
ZANTAC Injection (Aqueous solution)
MPI, EU: SmPC
UK
ZANTAC Tablets
MPI, EU: SmPC
UK